, new evidence indicates for all steroid hormones that their RR are mediated by a variety of receptor types located near or associated with the plasma membrane or its caveolae components (2). The time required for onset of the RR is system dependent and can vary from seconds (e.g. opening ion channels) to 10 -60 min (e.g. activation of phosphatidylinositol-3Ј-kinase or endothelial nitric oxide synthase). This contrasts with genomic responses, which generally take a few hours to days to become fully manifest and which can be blocked by inhibitors of transcription and translation.
S
TEROID HORMONES ARE able to serve as chemical messengers in a wide number of species and target tissues to transmit signals that result in both genomic and rapid responses (RR). The ability of steroid hormones, including 1␣,25(OH) 2 -vitamin D 3 [1␣,25(OH) 2 D 3 ] , to generate biological responses is defined by the presence of their cognate receptors in selected target organs and tissues. Although it is clear that steroid hormones' genomic responses are mediated by formation of a ligand-receptor complex with the cognate receptor of the superfamily of steroid hormone nuclear receptors (1) , new evidence indicates for all steroid hormones that their RR are mediated by a variety of receptor types located near or associated with the plasma membrane or its caveolae components (2) . The time required for onset of the RR is system dependent and can vary from seconds (e.g. opening ion channels) to 10 -60 min (e.g. activation of phosphatidylinositol-3Ј-kinase or endothelial nitric oxide synthase). This contrasts with genomic responses, which generally take a few hours to days to become fully manifest and which can be blocked by inhibitors of transcription and translation.
1␣,25(OH) 2 D 3 , which is a conformationally flexible molecule, is known to stimulate a wide array of RR; some examples include the rapid intestinal absorption of Ca 2ϩ (transcaltachia), secretion of insulin by pancreatic ␤-cells, opening of voltage-gated Ca 2ϩ and Cl Ϫ channels in osteoblasts, and the rapid migration of endothelial cells (2, 3) . Intriguingly, one shape of 1␣,25(OH) 2 D 3 is used for genomic responses, and a different shape serves as an agonist of RR (4) . The question then arose as to whether there was a second receptor, apart from the nuclear vitamin D receptor (VDR), which responded to the presence of a different shaped 1␣,25(OH) 2 D 3 to generate RR? The purpose of this minireview is to evaluate the VDR with respect to its involvement in genomic responses and then to review evidence that the same VDR is also involved in mediation of RR.
It has been generally assumed for receptor-ligand interactions that the ligand is frozen in a single conformation dictated by both the structural constraints of the ligand and the three-dimensional architecture of the peptide chains that create the ligand binding domain (LBD) of the receptor(s). The ligands for the thyroid receptor (T 3 ), the retinoic acid receptor (retinoic acid), and the VDR are all conformationally flexible, and the x-ray crystallographic structure for each receptor indicates that only one definitive conformer was present in each LBD (2) . This clearly demonstrates that steroid receptors can capture one ligand conformation from a very large population of flexible conformers. Figure 1 , A-C, summarizes the three structural features of 1␣,25(OH) 2 D 3 that empower its exceptional flexibility and as a consequence define its ability to generate a multitude of different agonist shapes for the VDR and other putative receptors. Figure 1 , E and F, illustrates the shape of the optimal ligand for VDR-mediated nuclear responses and for RR as well for a second protein of the vitamin D endocrine system, the plasma transport protein, or vitamin D binding protein (DBP), the x-ray structure of which has also been elucidated. It is clear that the VDR, DBP, and the receptor for 1␣, 25 Table 2 and text). E and F, Space-filling (E) and stick (F) representations illustrating the clear differences in the shapes of the three optimal ligands for the nuclear localized VDR (left), the membrane-caveolae localized VDR (middle), and the plasma DBP (right). The nuclear VDR ligand [1␣,25(OH) 2 D 3 ] is in a bowl-shaped twisted 6-s-trans conformation with the A-ring and side chain both 30°above the plane of the C/D-ring. The relatively planar 6-s-cis locked JN is a ligand for the membrane VDR. The DBP ligand [25(OH)D 3 ] is in a twisted 6-s-trans orientation with the A-ring C10 -C19 exocyclic alkene 30°below the plane of the C/D-ring and the side chain almost 90°below the C/D-ring plane. Each of the illustrated molecules has its 25-OH pointed to the right and the A-ring to the left. The shapes of the nuclear VDR (29) and DBP (34) ligands were learned from the separate determination of the x-ray structure of each protein, whereas the shape of the membrane VDR ligand was determined by computer modeling.
carried out an extensive structure-function study of the shape of the agonist required for optimal mediation of four separate RR; these include transcaltachia (duodenum), opening of voltage-gated Ca 2ϩ and Cl Ϫ channels (osteoblasts), insulin secretion from pancreatic ␤-cells, and smooth muscle cell migration (see Table 1 ). In these studies, the potency of 1␣,25(OH) 2 D 3 , to initiate the indicated RR was compared with that of 6-s-cis locked 1␣,25(OH) 2 -lumisterol (JN) and a 6-s-trans locked 1␣,25(OH)-dihydrotachysterol 3 (JB). In all four systems, the optimal shaped RR agonist was found to be the 6-s-cis locked JN, which was equipotent to that of 1␣,25(OH) 2 D 3 . Figure 1D illustrates the structure of JN, which is chemically locked in the 6-s-cis shape and which is a full agonist for RR (4) . As a consequence, any proposed receptor for a 1␣,25(OH) 2 D 3 -or JN-mediated RR must clearly have a LBD that can accommodate a 6-s-cis ligand shape.
A timeline summarizing the important developments in our understanding of the VDR and its historical involvement in genomic responses and now, more recently, its proposed involvement in RR is presented in Table 2 . The interval from its discovery in 1969 to 1984 established that the cell nucleuslocalized VDR, like those for the classical ligand-occupied steroid hormone receptors (the estrogen, progesterone, androgen, glucocorticoid, and mineralocorticoid receptors), is intimately involved with selective gene transcription appropriate to the biology of each system. The VDR is known to be present in over 30 target tissues in man (5) . Given the longstanding dogma that vitamin D is principally responsible for calcium homeostasis via actions in the intestine, bone, and kidney, the other 27 VDR-containing target organs collectively reflect new genomic response assignments for 1␣,25(OH) 2 D 3 and its VDR. Some of the new genomic frontiers include the immune system's B and T lymphocytes, the hair follicle, muscle, adipose tissue, bone marrow, and cancer cells.
The various chapters of 1␣,25(OH) 2 D 3 -mediated RR on the VDR from 1994 to the present are also summarized in Table  2 . The concept of the existence of a membrane receptor for 1␣,25(OH) 2 D 3 has its origins in the study of the process of 1␣,25(OH) 2 D 3 -mediated response of transcaltachia, or the rapid hormonal stimulation of intestinal Ca 2ϩ absorption in the perfused chick intestine (6) . The most potent agonist is the natural hormone 1␣,25(OH) 2 D 3 , which can stimulate the transport of calcium across the intestine within 4 -5 min of its injection in the celiac artery that perfuses the duodenum (6) .
The current view of this laboratory is that transcaltachia and many other 1␣,25(OH) 2 D 3 -mediated RR are initiated by a membrane-localized receptor that binds 1␣,25(OH) 2 D 3 (7) . Recent work in our laboratory has focused on isolation of the intestinal, kidney, or lung membrane fractions that contains caveolae. Caveolae are flask-shaped membrane invaginations that are enriched in the sphingolipids and cholesterol commonly found in both caveolae and/or lipid rafts (8) . The caveolae-enriched membrane fraction is isolated from chick or rat intestine, kidney, or lung tissue by Percoll buoyant density centrifugation. We find under both in vivo and in vitro conditions that there is a saturable binding of high-specificactivity tritiated 1␣,25(OH) 2 D 3 in the caveolae-enriched membrane fraction. This binding activity is steroid specific for 1␣-hydroxylated analogs and for 1␣,25(OH) 2 D 3 has a distribution constant (K d ) equal to 1.4 nm, which is identical to the nuclear VDR K d for 1␣,25(OH) 2 D 3 (7) . Furthermore, by confocal microscopy, we showed that green fluorescent labeled antibodies to the classical nuclear VDR colocalized with red fluorescent labeled antibodies to caveolin-1 in caveolae present in the plasma membrane of ROS-17.2,8 osteoblast cells (7) .
Both the author's laboratory (7) and that of Lieberherr and Garabedian (9) present in VDR-KO tissues was found to be attributable to the presence of a truncated form of the VDR present in the strain of VDR-KO mice employed in our studies (10) . Lieberherr and Garabedian found that in fibroblasts obtained from a patient with the genetic disease of vitamin D-resistant rickets, a single point mutation in the VDR (Lys45Glu) resulted in the loss of 1␣,25(OH) 2 D 3 RR (9).
Thus, this laboratory's view is that the classical VDR normally associated with the cell nucleus and gene transcription can also be resident near to or associated with caveolae present in the plasma membrane. It has also been reported that the estrogen receptor and androgen receptor are associated with caveolae of (2).
It is apparent that for the VDR there is a perceived problem, because a 6-s-trans shape of 1␣,25(OH) 2 D 3 is obligatory for genomic responses, whereas a 6-s-cis shape is required for RR. This then poses the conundrum as to how a receptor with one LBD can bind ligands of quite different shapes to gen- erate two quite different biological outcomes? Yet, the x-ray structure of the VDR revealed only one LBD, that which bound the 6-s-trans shape (see Fig. 1E ).
One possible solution to the conundrum was obtained from molecular modeling of the VDR (11) . Using the atomic coordinates of the x-ray structures of the VDR and computer modeling (see Fig. 2A ), we have been able to identify the presence of a putative alternative LBD in the VDR that can accommodate via computer docking either the appropriate natural hormone or analogs that are known to be agonists only for RR (see Fig. 2A ) (11) . Figure 2A illustrates for the VDR the classical nuclear ligand pocket (red) and the proposed alternative ligand pocket (blue). Each ligand pocket is envisioned to have separate portals. The entrance to the nuclear pocket is dependent upon helix 12 being in an open configuration so that the hormone/ligand can enter into the LBD pocket and gain access to integral H-bonding residues thereby fully occupying the genomic pocket. Next, helix 12 moves to reclose the portal. The surprising discovery is that the alternative pocket and the genomic pocket overlap. Each of these pockets uses the same hydrogen-bonding partners of the VDR to stabilize the A-rings of the bound ligands; however, the remaining interactions of the C/D-ring and side chain of the ligand in the genomic or alternative pockets are entirely unique. Although the K d of the genomic pocket is known from equilibrium binding experiments with The author's laboratory believes that the resolution of the conundrum stated above is to propose a receptor ensemble model that can describe how a classic steroid (nuclear) receptor could accommodate differently shaped ligands so as to result in the initiation of either rapid or genomic responses (Fig. 2B) . This model posits that unbound receptor macromolecules exist in the cytoplasm as multiple, equilibrating receptor conformations that follow the laws associated with standard statistical distributions (11) . Thus, a steroid hormone would sample the existing population of receptor conformations available and form a receptor-hormone complex with the receptor species that formed the best complementary fit between the two molecules; this would shift the equilibrium among the receptor species so as to favor the energetically most stable hormone-bound receptor conformation. It should be noted that 1␣,25(OH) 2 D 3 should be able to change its conformation much more quickly than the receptor protein, so essentially the whole ensemble of 1␣,25(OH) 2 D 3 conformations can sample each of the individual protein ensemble conformations. Implicit in this model is that the receptor sampling by the ligand involves gaining entrance and exploring the interior surface of the LBD to determine whether a complementary fit can be achieved. A related model to describe ligand/receptor-induced dissociation of rapid from genomic responses was included in the comprehensive analysis of nongenotropic, sex-nonspecific signaling by the estrogen and androgen receptors (12) . Although this model has not yet been fully validated, it is possible to identify experiments involving site-directed mutagenesis of the VDR that may give further insight. Figure 3 is a summary figure that integrates the signal One extraordinary challenge will be to identify and fully biochemically characterize the membrane-associated VDR. An equally daunting task will be to define in the various cell systems that display RR the identification of the specific signal transduction pathways that contribute to mediation of a specific rapid biological response. An additional important question is whether the membrane VDR can communicate with the nucleus of the cell to modulate gene transcription. In data not shown, but summarized in Fig. 3 (35) . In this example, transient occupancy of the alternative pocket by a ligand could/would lead to initiation of RR, whereas occupancy of the classical pocket by a ligand would lead to activation of genomic responses; both of these pockets are illustrated for the VDR in A. The alternative pocket is accessible in all three H12 conformers (a, b, and c). Occupancy of this alternative pocket is favored before achieving the steady-state equilibrium only for the receptor's natural ligands given the increased accessibility coupled with weaker van der Waals interactions compared with genomic pocket occupancy. Receptor conformer (c) is the only conformer able to accept ligands that can bind to the classical ligand binding site leading to genomic responses because in conformers a and b, H12 blocks ligand accessibility to the conserved H5 Arg residue located at the innermost part of the classic ligand binding pocket. An interesting consequence of the receptor ensemble concept may be that association of the nuclear receptor with caveolae or cell membranes may change the ligand binding preferences to favor the alternative pocket. Ligand occupancy of this genomic pocket is favored under steady-state conditions because of the increase in thermodynamic stability derived from hydrophobic interactions. It is possible that drug analogs, especially those related to the natural hormone(s), may have differential fractional occupancies of the two pockets, thus affecting the efficiency of the cellular signaling pathways mediated by either pocket. 
